RYTM · Rhythm Pharmaceuticals, Inc.
$102.10
+1.80% last session
End-of-day data · updated 2026-07-28
Market cap
$7B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-144.0
Dividend yield
—
Beta
1.88
Avg volume
1M
Employees
0K
2D change
3.95%
5D change
3.38%
10D change
-0.44%
30D change
-3.38%
60D change
20.17%
MTD change
-3.88%
YTD change
-0.85%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RYTM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-27
Latest call per bank · past 12 months
JP Morgan
Overweight$145
+42.0% vs priceRBC Capital
Outperform$141
+38.1% vs priceWells Fargo
Overweight$155
+51.8% vs priceCitigroup
Buy$142
+39.1% vs priceBank of America
Buy$149
+45.9% vs priceMorgan Stanley
Overweight$136
+33.2% vs priceGoldman Sachs
Buy$157
+53.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-27 | JP Morgan | Initiates | Overweight | $0.00 → $145 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $137 → $141 |
| 2026-06-16 | Canaccord Genuity | Maintains | Buy | $143 → $151 |
| 2026-06-15 | Wells Fargo | Maintains | Overweight | $144 → $155 |
| 2026-05-07 | Canaccord Genuity | Maintains | Buy | $140 → $143 |
| 2026-05-06 | RBC Capital | Maintains | Outperform | $136 → $137 |
| 2026-05-06 | Wells Fargo | Maintains | Overweight | $143 → $144 |
| 2026-03-23 | HC Wainwright & Co. | Maintains | Buy | $100 → $105 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.3% above the 50-day MA ($98.86).
- Price vs 200-day MA: Trading 9.2% above the 200-day MA ($98.97).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-1.13) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($75.82) and high ($117.62).
RYTM Price Chart
Loading chart for RYTM…
Fundamentals
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.